<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33000368</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1865-3774</ISSN><JournalIssue CitedMedium="Internet"><Volume>113</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>International journal of hematology</Title><ISOAbbreviation>Int J Hematol</ISOAbbreviation></Journal><ArticleTitle>Bone marrow transplantation from a human leukocyte antigen-mismatched unrelated donor in a case with C1q deficiency associated with refractory systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>302</StartPage><EndPage>307</EndPage><MedlinePgn>302-307</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12185-020-03004-7</ELocationID><Abstract><AbstractText>Human C1q deficiency is frequently associated with systemic lupus erythematosus (SLE), which requires long-term systemic corticosteroid administration. We report the case of a 12-year-old female patient with C1q deficiency presenting with intractable SLE who successfully underwent bone marrow transplantation from a human leukocyte antigen (HLA)-mismatched unrelated donor with an immunosuppressive conditioning regimen based on fludarabine, melphalan, and anti-thymocyte globulin. She developed Grade I graft-versus-host disease, but did not have any transplantation-related morbidity. Complete donor chimerism has been maintained for 2&#xa0;years after transplantation, leading to the restoration of C1q levels and the resolution of SLE symptoms. Normal C1q mRNA expression was observed in CD14&#x2009;+&#x2009;cells. Hematopoietic stem cell transplantation from an HLA-mismatched donor is a feasible treatment for patients with C1q deficiency with refractory SLE that is dependent on systemic corticosteroid treatment who do not have an HLA-matched donor.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matsumura</LastName><ForeName>Risa</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-4871-928X</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. rmats@hiroshima-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mochizuki</LastName><ForeName>Shinji</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maruyama</LastName><ForeName>Natsuki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morishita</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawaguchi</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okada</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsumura</LastName><ForeName>Miyuki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaji</LastName><ForeName>Shunsaku</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Tsuyama Central Hospital, Tsuyama, Okayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimizu</LastName><ForeName>Junya</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, National Hospital Organization Okayama Medical Center, Okayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimada</LastName><ForeName>Akira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatric Hematology and Oncology, Okayama University Hospital, Okayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Masao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Int J Hematol</MedlineTA><NlmUniqueID>9111627</NlmUniqueID><ISSNLinking>0925-5710</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006680">HLA Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>80295-33-6</RegistryNumber><NameOfSubstance UI="D015922">Complement C1q</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016026" MajorTopicYN="Y">Bone Marrow Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015922" MajorTopicYN="N">Complement C1q</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019468" MajorTopicYN="N">Disease Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006086" MajorTopicYN="N">Graft vs Host Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006680" MajorTopicYN="N">HLA Antigens</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006650" MajorTopicYN="N">Histocompatibility Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019172" MajorTopicYN="N">Transplantation Conditioning</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014184" MajorTopicYN="N">Transplantation, Homologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061349" MajorTopicYN="Y">Unrelated Donors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C1q deficiency</Keyword><Keyword MajorTopicYN="N">Hematopoietic stem cell transplantation</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>1</Day><Hour>5</Hour><Minute>40</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33000368</ArticleId><ArticleId IdType="doi">10.1007/s12185-020-03004-7</ArticleId><ArticleId IdType="pii">10.1007/s12185-020-03004-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sellar GC, Cockburn D, Reid KB. Localization of the gene cluster encoding the A, B, and C chains of human C1q to 1p34.1-1p36.3. Immunogenetics. 1992;35:214&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00185116</ArticleId></ArticleIdList></Reference><Reference><Citation>Schejbel L, Skattum L, Hagelberg S, &#xc5;hlin A, Schiller B, Berg S, et al. Molecular basis of hereditary C1q deficiency&#x2014;revised: identification of several novel disease-causing mutations. Genes Immun. 2011;12:626&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gene.2011.39</ArticleId></ArticleIdList></Reference><Reference><Citation>Nayak A, Ferluga J, Tsolaki AG, Kishore U. The non-classical functions of the classical complement pathway recognition subcomponent C1q. Immunol Lett. 2010;131:139&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2010.03.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott D, Botto M. The paradoxical roles of C1q and C3 in autoimmunity. Immunobiology. 2016;221:719&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2015.05.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Stegert M, Bock M, Trendelenburg M. Clinical presentation of human C1q deficiency: How much of a lupus? Mol Immunol. 2015;67:3&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2015.03.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Mayouf SM, Abanomi H, Eldali A. Impact of C1q deficiency on the severity and outcome of childhood systemic lupus erythematosus. Int J Rheum Dis. 2011;14:81&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1756-185X.2010.01574.x</ArticleId></ArticleIdList></Reference><Reference><Citation>van Schaarenburg RA, Schejbel L, Truedsson L, Topaloglu R, Al-Mayouf SM, Riordan A, et al. Marked variability in clinical presentation and outcome of patients with C1q immunodeficiency. J Autoimmun. 2015;62:39&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2015.06.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekinci Z, Ozturk K. Systemic lupus erythematosus with C1q deficiency: treatment with fresh frozen plasma. Lupus. 2018;27:134&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317741565</ArticleId></ArticleIdList></Reference><Reference><Citation>Topaloglu R, Taskiran EZ, Tan C, Erman B, Ozaltin F, Sanal O. C1q deficiency: identification of a novel missense mutation and treatment with fresh frozen plasma. Clin Rheumatol. 2012;31:1123&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-012-1978-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Norsworthy PJ, Hall AE, Kelly SJ, Walport MJ, Botto M, et al. SLE with C1q deficiency treated with fresh frozen plasma: a 10-year experience. Rheumatology (Oxford). 2010;49:823&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kep387</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson RF, Hagelberg S, Schiller B, Rdingden O, Truedsson L, &#xc5;hlin A. Allogeneic hematopoietic stem cell transplantation in the treatment of human C1q deficiency: the Karolinska experience. Transplantation. 2016;100:1356&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000000975</ArticleId></ArticleIdList></Reference><Reference><Citation>Arkwright PD, Riley P, Hughes SM, Alachkar H, Wynn RF. Successful cure of C1q deficiency in human subjects treated with hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2014;133:265&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2013.07.035</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi Y, Shimizu J, Hatanaka M, Kitano E, Kitamura H, Takada H, et al. The identification of a novel splicing mutation in C1qB in a Japanese family with C1q deficiency: a case report. Pediatr Rheumatol Online J. 2013;11:41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1546-0096-11-41</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabs U, Martin H, Hitschold T, Golan MD, Heinz HP, Loos M. Isolation and characterization of macrophage-derived C1q and its similarities to serum C1q. Eur J Immunol. 1986;16:1183&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.1830160926</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaul M, Loos M. Collagen-like complement component C1q is a membrane protein of human monocyte-derived macrophages that mediates endocytosis. J Immunol. 1995;155:5795&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pubmed">7499868</ArticleId></ArticleIdList></Reference><Reference><Citation>Faust D, Loos M. In vitro modulation of C1q mRNA expression and secretion by interleukin-1, interleukin-6, and interferon-gamma in resident and stimulated murine peritoneal macrophages. Immunobiology. 2002;206:368&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="doi">10.1078/0171-2985-00187</ArticleId></ArticleIdList></Reference><Reference><Citation>Petry F, Botto M, Holtappels R, Walport MJ, Loos M. Reconstitution of the complement function in C1q-deficient (C1qa-/-) mice with wild-type bone marrow cells. J Immunol. 2001;167:4033&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.167.7.4033</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes-Hernandez J, Fossati-Jimack L, Petry F, Loos M, Izui S, Walport MJ, et al. Restoration of C1q levels by bone marrow transplantation attenuates autoimmune disease associated with C1q deficiency in mice. Eur J Immunol. 2004;34:3713&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200425616</ArticleId></ArticleIdList></Reference><Reference><Citation>Horan J, Wang T, Haagenson M, Spellman SR, Dehn J, Eapen M, et al. Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders. Blood. 2012;120:2918&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-03-417758</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2020;7:e100&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(19)30220-0</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>